1. Pink Sheet
  3. >>Distribution/Supply Chain

Uncertain Times: New Lockdowns, Ukraine Challenge Chinese Pharma

 
• By Brian Yang

As residents of China's largest city brace for a possible prolonged lockdown, the gathering COVID-19 outbreak is set to cause some pharma disruption in the country, while broader geopolitical factors including Ukraine are hindering the industry's global ambitions. 

Beijing residents waiting in line to get PCR Testing on March 21 morning.
BEIJING RESIDENTS WAITING TO GET PCR TESTING ON MARCH 21, 2022 • Source: Brian Yang/Pink Sheet

Going into the third year of the global pandemic, residents of China's largest city are feeling uncertainty around potential extended lockdowns for the first time, the impact of which could affect a major research and headquarters hub for the pharma industry in the country.

Shanghai is reporting record numbers of COVID-19 infections, official data pointing to 977 asymptomatic cases and four confirmed infections as of 23 March, while the uptrend is also continuing in the northeastern Jilin province, which reported 2,320 confirmed infections and 528

More from Distribution/Supply Chain

Austria To Fine Companies For Violating New Drug Stockpiling Rule

 
• By Neena Brizmohun

A new ordinance for addressing drug shortages in Austria requires drug companies distributing any of the hundreds of products listed in an accompanying annex to maintain adequate stock in the country to meet patient demand for four months.

Switzerland Simplifies Imports Of Unauthorized Drugs To Tackle Drug Shortages

 
• By Eliza Slawther

Swiss authorities have introduced temporary measures that will make it easier for health care professionals to import medicines that are either not authorized or not available in Switzerland, which will particularly benefit pediatric drugs, in light of ongoing shortages.

Companies Advised To Assess Potential Impacts Of Landmark Global Pandemic Treaty

 
• By Neena Brizmohun

Mechanisms in the draft treaty that the more than 190 member states of the World Health Organization have finally agreed to are expected to “materially affect companies,” particularly those that develop, manufacture or distribute pandemic-related health care products.

Beyond Tariffs: The Silver Lining Of The US Pharma Security Investigation

 
• By Jessica Merrill

An investigation by the US Secretary of Commerce into pharmaceutical imports gives industry an opportunity to comment. AAM CEO John Murphy talked to Pink Sheet's sister publication Scrip about the latest developments.

More from Compliance